FDA approves bionic eye for adults with rare genetic disease

The following is an excerpt.

For most of us, light-sensitive cells that line our retinas convert light rays into electrical impulses that travel through the optic nerve to the brain to be assembled into images. But for an estimated 1 in 4,000 people in the U.S. with a genetic condition called retinitis pigmentosa, or RP, those cells are damaged, which most commonly impairs vision at night. What’s more, treatment to prevent eventual (if unlikely) total blindness remains elusive.

Enter the Argus II Retinal Prosthesis System, which the FDA approved today [14 February 2013] to treat a very specific population: adults 25 and older with severe to profound RP who have bare or no light perception in both eyes but inner layer retinal function and a history of the ability to see forms.

View the original article here: FDA approves bionic eye for adults with rare genetic disease

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: What are mRNA COVID-19 vaccines and how do they work?

Infographic: What are mRNA COVID-19 vaccines and how do they work?

As of 1 December 2020, thirteen vaccines have reached the final stage of testing: where they are being given to ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend